Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses
<p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p&...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Faculty of Medicine Universitas Indonesia
2012-02-01
|
Series: | Medical Journal of Indonesia |
Online Access: | http://mji.ui.ac.id/journal/index.php/mji/article/view/474 |
id |
doaj-5b38b19628b24306ac3e681ac5a2e5eb |
---|---|
record_format |
Article |
spelling |
doaj-5b38b19628b24306ac3e681ac5a2e5eb2020-11-25T02:17:48ZengFaculty of Medicine Universitas Indonesia Medical Journal of Indonesia0853-17732252-80832012-02-01211445110.13181/mji.v21i1.474471Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analysesLaurentius A. PramonoBirry KarimWulyo RajabtoParlindungan SiregarNanang SukmanaBambang Setyohadi<p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p><p><strong>Methods:</strong> Method in this case study is evidence-based case report using meta-analyses. Clinical question used in this paper is; which immunosuppressant gives better result in achieving remission in lupus nephritis patient: cyclophosphamide or mycophenolate mofetil? To answer this question, we search the evidence from PubMed with the keywords: “lupus nephritis AND mycophenolate mofetil AND cyclophosphamide” with inclusion criteria of meta-analysis, written in English, and focused comparing cyclophosphamide and mycophenolate mofetil.<br /><strong></strong></p><p><strong>Results:</strong> From the searching method, we found 11 articles which is relevant. One has been excluded since it written in Hebrew, 4 articles excluded since are not focus answering the clinical question. At the end, 6 studies were included to the critical appraisal step.<br /><strong></strong></p><p><strong>Conclusion:</strong> Based on the evidences, mycophenolate mofetil is non-inferior to cyclophosphamide in achieving remission in lupus nephritis patients, but with the better safety profile. Patient in our case study get mycophenolate mofetil and shows better clinical condition towards remission as she are evaluated in the outpatient clinic. <em><strong>(Med J Indones 2012;21:44-51)</strong></em></p><p><strong>Keywords:</strong> <em>Cyclophosphamide, evidence-based case report, lupus nephritis, meta-analysis, mycophenolate mofetil, remission, systematic review</em></p>http://mji.ui.ac.id/journal/index.php/mji/article/view/474 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laurentius A. Pramono Birry Karim Wulyo Rajabto Parlindungan Siregar Nanang Sukmana Bambang Setyohadi |
spellingShingle |
Laurentius A. Pramono Birry Karim Wulyo Rajabto Parlindungan Siregar Nanang Sukmana Bambang Setyohadi Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses Medical Journal of Indonesia |
author_facet |
Laurentius A. Pramono Birry Karim Wulyo Rajabto Parlindungan Siregar Nanang Sukmana Bambang Setyohadi |
author_sort |
Laurentius A. Pramono |
title |
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
title_short |
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
title_full |
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
title_fullStr |
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
title_full_unstemmed |
Mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
title_sort |
mycophenolate mofetil versus cyclophosphamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses |
publisher |
Faculty of Medicine Universitas Indonesia |
series |
Medical Journal of Indonesia |
issn |
0853-1773 2252-8083 |
publishDate |
2012-02-01 |
description |
<p><strong>Background:</strong> The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.<br /><strong></strong></p><p><strong>Methods:</strong> Method in this case study is evidence-based case report using meta-analyses. Clinical question used in this paper is; which immunosuppressant gives better result in achieving remission in lupus nephritis patient: cyclophosphamide or mycophenolate mofetil? To answer this question, we search the evidence from PubMed with the keywords: “lupus nephritis AND mycophenolate mofetil AND cyclophosphamide” with inclusion criteria of meta-analysis, written in English, and focused comparing cyclophosphamide and mycophenolate mofetil.<br /><strong></strong></p><p><strong>Results:</strong> From the searching method, we found 11 articles which is relevant. One has been excluded since it written in Hebrew, 4 articles excluded since are not focus answering the clinical question. At the end, 6 studies were included to the critical appraisal step.<br /><strong></strong></p><p><strong>Conclusion:</strong> Based on the evidences, mycophenolate mofetil is non-inferior to cyclophosphamide in achieving remission in lupus nephritis patients, but with the better safety profile. Patient in our case study get mycophenolate mofetil and shows better clinical condition towards remission as she are evaluated in the outpatient clinic. <em><strong>(Med J Indones 2012;21:44-51)</strong></em></p><p><strong>Keywords:</strong> <em>Cyclophosphamide, evidence-based case report, lupus nephritis, meta-analysis, mycophenolate mofetil, remission, systematic review</em></p> |
url |
http://mji.ui.ac.id/journal/index.php/mji/article/view/474 |
work_keys_str_mv |
AT laurentiusapramono mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses AT birrykarim mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses AT wulyorajabto mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses AT parlindungansiregar mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses AT nanangsukmana mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses AT bambangsetyohadi mycophenolatemofetilversuscyclophosphamidefortherapyoflupusnephritisanevidencebasedcasereportfromsystematicreviewsandmetaanalyses |
_version_ |
1724884952253726720 |